E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hereditary neuropathic amyloidosis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 11. |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019889 |
E.1.2 | Term | Hereditary neuropathic amyloidosis |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principal objective of this study is to determine whether diflunisal inhibits disease progression in patients with familial amyloid polyneuropathy (FAP). Peripheral neuropathy (temperature/vibratory or light touch sensory loss, parasthesias), the most common feature of familial amyloidosis ,is the primary end point of this study. Worsening peripheral neuropathy indicates disease progression. Neurologic Impairment Score (NIS), a highly quantitative assessment of peripheral neurologic function employed in studies of diabetic neuropathy, will be the primary outcome measure. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are as follows:
-Kumamoto Neurologic Scale to assess autonomic dysfunction, sensori-motor peripheral neuropathy, and visceral organ involvement of FAP using a qualitative, office-based measure. -Echocardiographic readings to determine the rate of heart change in FAP in the presence and absence of the study drug. -Medical Outcomes Study 36-item Short Form General Health Survey (SF-36) - a quality of life measure validated in patients with systemic amyloidosis. -Amyloid Content in Aspirated Fat Tissue - a rough measure of total body amyloid burden. -modified Body Mass Index - validated as an outcome predictor in a post-liver transplant FAP cohort; we will correlate serial measures to neurologic disease course in this patient population
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Biopsy proven amyloid deposition 2. Genotyping of variant TTR 3. Signs of peripheral or autonomic neuropathy -- detectable by a neurologist (performance status ≤ 3) 4. Age ≥ 18 and ≤ 75 years 5. Negative βHCG testing and contraception for sexually active women of child-bearing potential |
|
E.4 | Principal exclusion criteria |
1. Use of non-study NSAIDs after enrollment (low dose aspirin allowed) 2. Other causes of sensorimotor polyneuropathy a. Vitamin B12 deficiency b. HIV patients on anti-retroviral drugs c. Diabetes mellitus (Hgb A1C > 6.2%) d. Chronic alcoholism (> 6 ounces hard liquor daily for 10 or greater years) 3. Co-morbidities with anticipated survival <2 years or liver transplantation in <1 yr 4. Liver transplantation 5. End-stage neuropathic disease (performance status > 3, parenteral nutrition, bedsores) 6. NYHA class IV (cardiac symptoms at rest & with minimal exertion) 7. Pregnancy or unwillingness to use contraception by women of childbearing age 8. Renal insufficiency (creatinine clearance < 30 ml/min) 9. Active or recent non-hemorrhoidal GI bleeding (within past 18 months) 10. Current anti-coagulation therapy, non-study NSAID or aspirin use 11. AST, ALT or Total Bilirubin > twice the upper limit of normal lab value 12. Non-steroidal or aspirin allergy/hypersensitivity 13. Thrombocytopenia (< 100,000 platelets/mm3) 14. Previous participation in this study 15. Inability or unwillingness of subject or legal guardian/representative to give written informed consent |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is the NIS+7 composite neurologic scoring system. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study will be defined as last patient last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |